Aus company secures $125m order for high power laser weapon
An Australian technology company has secured a 'groundbreaking' $125 million deal with a European country for a 'high energy laser weapon system' designed to shoot down over a dozen drones within a minute.
Electro Optic Systems (EOS) signed a contract with a European NATO Member State – the name of which has not been disclosed – to deliver the 100-kilowatt anit-drone weapon between 2025-2028.
'The new laser counter-drone capability was developed by EOS to address the urgent market need and emerging strategic requirement to defend against drone swarm attacks at an economical cost,' EOS said in a statement on its website.
'This is the world's first export order for a 100-kilowatt class laser defence system.'
The high energy laser weapons was designed to defend against drone swarm attacks. Picture: Supplied/Electro Optic Systems
The company said the order, which is valued at €71.4 million (or about $A125 million), will be fulfilled in Singapore, where EOS has a laser innovation centre.
'EOS is already an established global leader in counter-drone capability using kinetic weapons and missiles to bring down drones. The high-power laser builds on these core competencies and substantially extends them.'
The system – which is mobile and can work on a truck – operates 'at the speed of light' and can shoot down as many as twenty drones in a minute, Dr Andreas Schwer, Chief Executive Officer of Electro Optic Systems told news.com.au.
'The laser can hit a target almost instantly … unlike a bullet which takes a second to get there,' Dr Schwer said.
The order is valued at $A125 million. Picture: Electro Optic Systems
The laser can hit a target almost instantly. Picture: Electro Optic Systems
He said the system works by amplifying lasers to high power levels.
'(It) then combines multiple laser beams together,' he explained.
'It tracks targets very accurately – this is critical – and keeps the laser beam on the target … The light energy typically degrades the drone target in 1-2 seconds.'
While missiles generally have a longer range, the high-power laser system 'can shoot down many more targets' at a cheaper cost within a two to five kilometre range.
'Missile systems cost $0.5m – $2.0m per shot fired,' Dr Schwer said.
'The laser system costs less than 10 cents per shot.'
'Lasers can shoot directly upwards, which ballistics (bullets and missiles) often cannot do,' he added.
A Russian drone attacks a building during a Russian missile and drone air attack in Kyiv, Ukraine, June 17, 2025. Picture: AP Photo/Efrem Lukatsky
With drones becoming increasingly more common in modern warfare and swarms posing a 'real threat', Dr Schwer said militaries will need to employ a 'layered solution', including laser systems, rocket systems and longer-range missiles to protect their valuable assets.
'Drones are a big threat both in military and civil domains,' he said.
'Because drones get cheaper every year, everyone is using them and many valuable assets are very vulnerable.'
He noted other countries are trying to develop laser weapon technology, 'but it is very complex'.
'This is the first very international supply contract of this size in the laser weapon industry – a groundbreaking deal for our industry and for EOS,' he said in a video on the company's website.
Looking to the future, Dr Schwer said laser weapons will continue to play a role on the battlefield, becoming more powerful and portable over time.
Going forward, the company is looking to expand its 50 to 100 kilowatt family and develop systems towards the 150 kilowatt class to meet future needs.
'We are also looking to develop naval variants of our models, giving the critical gap in the market for effective counter-drone solutions.'
Russia tests laser defences
It comes as Russia last month conducted large-scale tests of new laser systems to defend against drones – which both Ukraine and Russia have deployed during the nations' three year war.
'These technologies will form one of the key elements of the universal air defense system President Vladimir Putin recently called for,' the Board of the Military-Industrial Complex said in a statement.
'The test results will be used to refine existing models and create systems capable of providing reliable protection against modern air attack weapons.'
Russian soldiers prepare a strike FPV drone aircraft to fly towards Ukrainian position in an undisclosed location. Picture: Russian Defense Ministry Press Service/AP
Meanwhile, Ukraine last year announced it had developed its own laser weapon which can target and down aircraft at altitudes exceeding two kilometres.
Speaking at the 'European Defense Industry: Prospects for Cooperation with the Ukrainian Defense Industry' conference in December, Colonel Vadym Sukharevskyi said the country's military proudly declared Tryzub (trident) 'laser is real and operational', adding that efforts were underway to scale up its capabilities against Russia.
Colonel Sukharevskyi also introduced the concept of 'mother drones' or 'queen drones' — unmanned aerial systems capable of carrying two FPV (first-person view) light attack drones during his address.
According to the Kyiv Independent, the announcement marked a significant leap in Ukraine's military innovation.
Originally published as 'Speed of light': Australian company secures 'groundbreaking' $125m order for high power anti-drone weapon
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
a minute ago
- News.com.au
Diggers and Dealers: Tim Hoff looks for more winners with his 2025 Diggers portfolio
Each year we catch up with Canaccord Genuity mining analyst Tim Hoff at Diggers and Dealers in Kalgoorlie to get his best ideas for the year ahead. Check out where he's looking for value in 2025. After an enormously successful 2023 instalment, Canaccord's Tim Hoff has had reason to be chirpy about his Diggers and Dealers stock selections. Powered by market darlings Spartan Resources (ASX:SPR) and Azure Minerals (ASX:AZS), a $10,000 investment in August 2023 would have netted $21,600 by last year's conference. Last year, Hoff correctly predicted small cap punting would be a harder task in turbulent markets. Spreading himself thinner across 13 small cap names, a 105% 12-month lift in copper explorer Prospect Resources (ASX:PSC) and 95% gain for South American silver stacker Andean Silver (ASX:ASL) proved the standouts of a kaleidoscopic mix of speculative names. All up the gains and losses of a hypothetical 'Hoff Diggers portfolio' would have evened out to 10.85% on the year. "Look last year we were sitting here and we thought it would be difficult," he said. "And honestly I hadn't looked at the numbers until today and I was fairly surprised to see that the portfolio, the ideas that we came through with on average were up. "When we break down some of the trends within that, you can see some of the exploration plays had a hard time. "That is the nature of exploration and greenfields exploration. You can see gold and precious metals benefited from positive commodity pricing, so that that really flowed through. And then the base metals where we were a little bit split between the names we had there, we had a couple of winners and a couple of losers. "When we take a step back, I feel like the year panned out roughly how we were thinking." Another $10,000 investment would have taken the hypothetical portfolio to $11,085, or if Hoff's take from 2023 were compounded, a $23,944 pool would be sitting there to take off the table or go again. So what is Tim Hoff eyeing this time around? Looking for discoveries The big thing Hoffy is looking for is small caps with the potential to make a discovery. That's getting easier in the gold space, where record prices are stirring rising valuations, with exploration budgets lifting as capital raises become easier and less dilutive. But it's a double-edged sword. Hoff is looking for stocks that can go multiple times, and a number of gold names are already running hard. And it's not just the now heavily covered gold sector where discoveries and rerates are on the cards. "Obviously we had Trump come through in November, and that's set a whole series of events in place like the bull run in gold pricing, with the rare earths sector certainly performing very well on the back of that. "And so there's always something happening in this market and pockets of interest." Hoff's 2025 Diggers portfolio Prospect Resources (ASX:PSC) Prospect is the only repeat entry in this year's picks from the Canaccord number cruncher. It owns the Mumbezhi project in Zambia, where Prospect has already outlined one of the largest undeveloped copper deposits on the ASX with over 500,000t of copper metal at grades of 0.5% Cu. That puts it right in the wheelhouse of neighbour First Quantum Minerals, which picked up a 15% stake in the junior this year as questions circle the long-term future of its nearby Sentinel mine. Hoff is doubling down even after a ripping 12-month run. "This is a coverage stock that I have on take-out watch. Right next door to their project in Zambia, you have 60 million tonnes of processing capacity. " It's owned by First Quantum. In 2029, the grade falls from 0.5% to 0.3%, and 2034 they run out of ore. You've got billions of dollars of sunk cost infrastructure there. And having that sit idle is not a tenable situation for a company like First Quantum. "So we think they'll get taken out. And if they don't we think that the project and the deposit has the potential to seriously grow tonnes from here, which is why I still think it's heavily undervalued at the moment. " It's heavily discounted still by the market, which hasn't yet come to fully grasp what's going on there." Loyal Metals (ASX:LLM) A lithium refugee, Loyal had its big coming out party in July when it procured the Highway Reward copper-gold mine in Queensland. It's now up 122% over the past month. One of the world's highest grade copper mines historically, past production saw 3.65Mt at 5.7% Cu and another 260,000t of gold ore at 4.5g/t Au. Since mining ended 20 years ago, copper prices have risen 680% and gold 1256%. "It's a high-grade copper project. It was smaller tonnes, it's a smaller footprint, but Loyal are looking for depth extensions, and there's been nothing done on this project for 20 years. No major modern geophysics, no drill program. " So they're looking for proximal discoveries, discoveries at depth or some targets that were never tested. So that's really exciting to us. "Market cap's about $25 million at the moment. We're starting from a nice low base there." Peak Minerals (ASX:PUA) Peak Minerals is one of a number of small caps enjoying the emergence of the Cameroon exploration scene, where it and DY6 Metals (ASX:DY6) have made rutile discoveries and Canyon Resources (ASX:CAY) is progressing its Minim Mirtap bauxite project. It was on a trip to Cameroon to see the latter that Peak piqued the interest of Hoff. "They're in the process of discovering what looks to be significant rutile discovery. Now mineral sands, there are varying grades and assemblages from lower value to higher value. "What they're discovering appears to me to be a really high value mineral sands discovery. "The stock's performed really well over the last couple of months. But I think ... this is when we see global scale projects, often the market will trail the results. And I think if this was in Western Australia, it'd be a much bigger company already. "The fact that it's in Cameroon and … I don't know anyone else who's been there, I think that holds investors back sometimes and provides the opportunity for those willing to look over the border." Q2 Metals Corp (TSX-V:QTWO) For the first time, Hoffy is taking his hunt for deep value global with TSX.V-listed Q2, which runs at a market cap of just C$117m. That betrays the very large potential resource its attempting to drill out at the Mia lithium project in Quebec. Lithium prices are, as is well known, in the dunny. But recent spot price increases and optimism that demand could soon overtake supply again has analysts thinking more proactively about underappreciated opportunities in the space. "We've written research on this. We think there's 207 million tonnes of spodumene there at grades of 1.3% lithium or more," Hoff said. "That puts this as potentially the sixth largest deposit in the world, sitting there with a fairly low market cap at the moment relative to that. "So I think any recovery that we see in the lithium market will translate to names like this, where there's a huge valuation gap between Patriot and Q2. Q2 is further down the line, but 200 million tonnes, again, this is something really big and their exploration target recently was even bigger than that." Torque Metals (ASX:TOR) Hoff's last pick is his only gold name, the Tolga Kumova-backed Torque. It has assets in Canada and Australia, primarily focused on the Paris gold project near Kambalda and Kalgoorlie in WA's Eastern Goldfields. "Torque's got some really interesting discovery holes coming through for a 100-mil market cap business at the moment. "Gold being that hot, it won't take long for the market's eyes turn to some of the results and you'll see the share price performance come behind that." The views, information, or opinions expressed in the interviews in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead does not provide, endorse or otherwise assume responsibility for any financial product advice contained in this article. At Stockhead, we tell it like it is. While Loyal Metals, DY6 Metals and Prospect Resources are Stockhead advertisers, they did not sponsor this article.
News.com.au
8 minutes ago
- News.com.au
Health Check: Probe steriliser Nanosonics cleans up with second FDA approval
Nanosonics has hit the double jackpot with its second FDA approval for the year Investor fatigue? Amplia shares tumble after further encouraging pancreatic cancer trial data Duelling parties in the Mayne Group (non) takeover offer stick to their bazookas Despite the turmoil afflicting the US Food & Drug Administration (FDA), Australian applicants are not walking away empty handed. Nanosonics (ASX:NAN) has got what it wanted, with the agency approving next-gen versions of its medical probe steriliser, Trophon. The assent paves the way for the company to launch the all-new Trophon 3 and a software upgrade for Trophon 2 users, Trophon 2 Plus (of course). These iterations include better digital integration and traceability features, with 40% faster cycle times. Nanosonics estimates the new device opportunity in its key US market at 10,000 units. This is for first-gen Trophon users upgrading to Trophon 3. The company commercialised the original Trophons in 2009. There's also scope to upgrade 20,000 current Trophon 2 users to Trophon 2 Plus. While there's new life in the Trophons, investor attention has turned to an entirely different product, Coris. This device is for flexible endoscopes such as colonoscopy probes. The FDA approved Coris in March and the company plans to roll out the units in the current half. Flexible endoscopes have 'complex channels' prone to biofilm build-up, so we're not talking about a quick spray with Handy Andy. The Coris opportunity could be bigger than that for the Trophons. Nanosonics is our third-biggest device company behind Cochlear and Resmed. The company's shares this morning gained as much as 11% on the news. Amplia's pancreatic cancer drug is 'superior to chemo alone' Investors are delivering a reality check to tearaway pancreatic drug developer Amplia (ASX:ATX), even though its trial update today delivers more positive news. Amplia said the combination of the company's drug candidate AMP-945 (narmafotinib) and chemo 'continues to outperform chemotherapy across a variety of measures'. Seven of the 17 patients have been on the trial for more than 12 months, for a mean 202 days versus 117 days for a comparative chemo-only trial. The company reports progression-free survival of 7.6 months, two months better than chemo. The treatment also maintained superiority relative to a more aggressive chemo treatment, Folfirinox. Earlier, Amplia excited investors and patients alike with two 'complete responses' in its phase Ib/II study – an unexpected result for such a difficult disease. The shares soared up to 425% (to 42 cents) after the company announced the first complete response – compete tumor disappearance – on June 16. On July 23 Amplia unveiled a $27.5 million equity raising at 23 cents per share, a 19% discount. The stock fell up to 29% this morning, perhaps because today's disclosure lacked the 'wow' factor relative to the earlier 'cure' revelations. Amplia is eyeing a follow-on phase IIb/III in late 2026. Telix's bad news 'triple whammy' Will the radiopharmacy giant's potential upcoming good news outweigh the 'triple whammy' of recent bad timings? Telix Pharmaceuticals' (ASX:TLX) innocuous-looking recasting of its historical financials on Tuesday spurred a sharp selloff, because the company revealed higher-then-expected costs. Telix said operating expenditure would be about 36% in the first (June) half, excluding research and development. This amounts to around US$140 million ($220 million). The company formally reports on August 21. 'Telix's US operations have expanded significantly following a number of acquisitions, including RLS Radiopharmacies, which completed on 27 January 2025,' Telix said by way of explanation. RLS was the last of five Telix purchases since February 2024, totalling $665 million. 'The impact of these additional expenses appears to have been underestimated in consensus earnings ,' posits Bell Potter's John Hester. He says Telix has endured a 'triple whammy' of setbacks. In late April the FDA declined to approve its brain cancer imaging agent Pixclara 'in its current form'. On July 22 the company revealed a Securities and Exchange Commission request for information, relating to the company's disclosure around its prostate cancer therapy programs. However, the FDA this month is likely to approve its kidney cancer imaging agent Zircaix. In October US reimbursement authorities will rule on favourable 'transitional pass through' payments for the company's second prostate cancer imaging agent, Gozellix. Telix shares have fallen by more than one third over the last six months. Most analysts value the stock at the $30-plus level, implying at least 50% upside. In the Mayne, the takeover stalemate endures The Mayne Pharma (ASX:MYX) takeover – or non-takeover – saga is no closer to resolution, with (non) bidder Cosette Pharmaceuticals making it clear it has no intention of executing the scheme implementation deed (SID). The Mayne camp, meanwhile, are sticking to their legal bazookas to enforce the $7.40 a share cash offer. Mayne last night disclosed that the company had received another notice from Cosette, alleging that Mayne breached misleading or deceptive conduct laws and continuous disclosure obligations. If that's the case, this might give further cause for Cosette to walk away from the SID struck in February. Cosette 'indicates an intention to terminate the SID if the circumstances giving rise to the alleged breach continue for five business days'. For its part, Mayne intends to force Cosette to 'perform its obligations under the SID' and on June 4 filed court proceedings to that effect. We can't remember any reluctant bidder being forced to follow through with a takeover (especially a foreign one such as the New Jersey-based Cosette). With Mayne shares not within coo-ee of the offer price, investors rate the prospect of this happening at about zero. Meanwhile, Mayne's August 29 full-year numbers will provide an insight into how the specialty drugmaker is faring operationally, amid the high-level distractions. You BARDA believe it, we're unprepared for the next pandemic In today's instalment of What Will RFK Junior Do Next, the health secretary has ordered the US disaster preparedness agency to cease US$500 million of funding for messenger RNA (mRNA) vaccines. Rather than using a weakened virus, mRNA vaccines 'instruct' cells to produce proteins to trigger an immune response. The Biomedical Advanced Research and Development Authority (BARDA) will terminate 22 vaccine grants. RFK Jr says the jabs 'fail to protect effectively' against upper respiratory infections including Covid and flu. 'We reviewed the science, listened to the experts and acted,' he says. Biotech newsletter Stat says: 'vaccine experts and people steeped in pandemic preparedness expressed horror at the news'.
News.com.au
31 minutes ago
- News.com.au
First-time buyer snaps up former presbytery at five-way auction
A quintet of buyers' hunger to take a bite out of turning a 120-year-old former presbytery into a beautiful new home have earned a keen price a local Catholic Church. The circa-1906 residence alongside four newly subdivided vacant blocks were carved out from the still operational St John the Baptist Church in Winchelsea. Five bidders raised a hand for the 1237sq m property at 3 Mercer St, as the home was offered with a $440,000 reserve price. It sold at the marathon auction for $515,000. Hayeswinckle Highton agent Michelle Winckle said the rare Federation style dwelling had never been on the market before. 'It was full of character. It needed significant work done, yes, because it was a church's house, so it needed to be turned into more of a home and it had been quite abandoned over the last few years,' Ms Winckle said. 'But the potential to renovate and restore a beautiful home was the main thing that the buyers fell in love with. 'And with the reserve of $440,000 all the first-home buyers within the area could see that they could pick up a beautiful character home on a 1200sq m block right near the river.' Ms Winckle said the $400,000 to $440,000 guide represented the property's land value, but it was a beautiful house to upgrade. The weatherboard house retains original period features such as 3.7m ceilings, high skirting boards and ornate timber mantels. A series of flexible rooms, including one with a bay window and a basic kitchen and meals area, sit off a wide central hallway. There's also scope to extend, subject to council approval, or add an outdoor entertainment area or garaging, taking advantage of the property's rear access. The property was nearly knocked down to a bidder for $485,000 before another emerged, adding $30,000 to the eventual sale price. Ms Winckle said Winchelsea's surf coast hinterland location had created a lifestyle hot spot. 'People that can't afford the coastal areas, they can come 20 minutes to Winchelsea, which is half an hour to Geelong, Colac, Lorne, Torquay, Anglesea, Airey's Inlet. 'It's half an hour to everything – it's so central – Winchelsea has got so much potential because it's sitting right there. 'It's easy to access Geelong on the ring road and it's quick to access Melbourne and you're getting a much larger block. 'You've still got the river, you've got a town that's growing, so people are seeing more potential for growth there than possibly an area where Torquay has already been massively commercialised.'
